Rhizopus Infection in a Preterm Infant: A Novel Use of Posaconazole

Pediatr Infect Dis J. 2020 Apr;39(4):310-312. doi: 10.1097/INF.0000000000002554.

Abstract

Posaconazole is a triazole antifungal with activity against Rhizopus, but data on its use and pharmacokinetics in preterm infants are scarce. In this case, a 24 4/7-week neonate's Rhizopus infection is successfully treated with debridement and combination antifungal therapy with amphotericin B, micafungin and enteral posaconazole. This is the first reported posaconazole use in a preterm neonate with Rhizopus.

Publication types

  • Case Reports

MeSH terms

  • Amphotericin B / therapeutic use
  • Antifungal Agents / therapeutic use*
  • Drug Therapy, Combination
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Male
  • Micafungin / therapeutic use
  • Microbial Sensitivity Tests
  • Mucormycosis / diagnosis
  • Mucormycosis / drug therapy*
  • Rhizopus / drug effects
  • Triazoles / therapeutic use*

Substances

  • Antifungal Agents
  • Triazoles
  • posaconazole
  • Amphotericin B
  • Micafungin

Supplementary concepts

  • Rhizopus infection